UB Paderborn / Katalog / Suche / in CDI

1 – 19 von 19

Sortiert nach

Results From the First‐in‐Human Study With Ozanimod, a Novel, Selective Sphingosine‐1‐Phosphate Receptor Modulator

Journal of clinical pharmacology, 2017-08, Vol.57 (8), p.988-996

2017

Link zum Volltext

Verfügbarkeit prüfen

Cardiac Safety of Ozanimod, a Novel Sphingosine‐1‐Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study

Clinical pharmacology in drug development, 2018-03, Vol.7 (3), p.263-276

2018

Link zum Volltext

Verfügbarkeit prüfen

Rationally Designed High-Affinity 2-Amino-6-halopurine Heat Shock Protein 90 Inhibitors That Exhibit Potent Antitumor Activity

Journal of medicinal chemistry, 2007-06, Vol.50 (12), p.2767-2778

2007

Link zum Volltext

Verfügbarkeit prüfen

Orally Active Purine-Based Inhibitors of the Heat Shock Protein 90

Journal of medicinal chemistry, 2006-01, Vol.49 (2), p.817-828

2006

Link zum Volltext

Verfügbarkeit prüfen

Antiproliferatiye effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units

Anti-cancer drugs, 1998-04, Vol.9 (4), p.327-332

1998

Link zum Volltext

Verfügbarkeit prüfen

Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units

Anti-cancer drugs, 1998-04, Vol.9 (4), p.327-331

1998

Link zum Volltext

Verfügbarkeit prüfen

Recombinant human factor IX : Replacement therapy, Prophylaxis, and pharmacokinetics in canine hemophilia B

Blood, 1996-10, Vol.88 (7), p.2603-2610

1996

Link zum Volltext

Verfügbarkeit prüfen

Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase

The Journal of biological chemistry, 1991-05, Vol.266 (13), p.8156-8161

1991

Link zum Volltext

Verfügbarkeit prüfen

Site-directed mutagenesis in human tissue-plasminogen activator. Distinguishing sites in the amino-terminal region required for full fibrinolytic activity and rapid clearance from the circulation

The Journal of biological chemistry, 1990-04, Vol.265 (10), p.5540-5545

1990

Link zum Volltext

Verfügbarkeit prüfen

Replacement of finger and growth factor domains of tissue plasminogen activator with plasminogen kringle 1. Biochemical and pharmacological characterization of a novel chimera containing a high affinity fibrin-binding domain linked to a heterologous protein

The Journal of biological chemistry, 1991-02, Vol.266 (6), p.3715-3723

1991

Link zum Volltext

Verfügbarkeit prüfen

The disposition of ethiofos (WR-2721) in the isolated perfused rat liver

Radiation research, 1989-02, Vol.117 (2), p.334

1989

Link zum Volltext

Verfügbarkeit prüfen

MRGPRX2 Antagonist EP262 Potently Inhibits Agonist-Induced Mast Cell Degranulation In Vitro and In Vivo

Journal of allergy and clinical immunology, 2023-02, Vol.151 (2), p.AB203-AB203

2023

Link zum Volltext

Verfügbarkeit prüfen

Synthesis and Biological Evaluation of a New Class of Geldanamycin Derivatives as Potent Inhibitors of Hsp90

Journal of medicinal chemistry, 2004-07, Vol.47 (15), p.3865-3873

2004

Link zum Volltext

Verfügbarkeit prüfen

Sa1222 Results of a Safety and Tolerability Study of Rpc1063, a Novel Orally Administered Sphingosine-1-Phosphate Receptor 1 (S1p1r) Agonist, in Healthy Adult Volunteers

Gastroenterology (New York, N.Y. 1943), 2013-05, Vol.144 (5), p.S-234-S-234

2013

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, pharmacodynamics, allometry, and dose selection of rPSGL-Ig for phase I trial

The Journal of pharmacology and experimental therapeutics, 2000-05, Vol.293 (2), p.618

2000

Link zum Volltext

Verfügbarkeit prüfen

358 A Small Molecule S1P1 Receptor Agonist With Significant Efficacy in Animal Models of Inflammatory Bowel Disease (IBD)

Gastroenterology (New York, N.Y. 1943), 2012-05, Vol.142 (5), p.S-84-S-84

2012

Link zum Volltext

Verfügbarkeit prüfen

Sa1221 Rpc1063, a Potent, Selective S1P1 Receptor Modulator, Is Active in a Therapeutic IBD Model and Exhibits Favorable PK/PD Properties in Healthy Volunteers

Gastroenterology (New York, N.Y. 1943), 2013-05, Vol.144 (5), p.S-234-S-234

2013

Link zum Volltext

Verfügbarkeit prüfen

Dimeric ansamycins—A new class of antitumor Hsp90 modulators with prolonged inhibitory activity

International journal of cancer, 2007-02, Vol.120 (4), p.918-926

2007

Link zum Volltext

Verfügbarkeit prüfen

The Importance of N- and O-Linked Oligosaccharides for the Biosynthesis and In Vitro and In Vivo Biologic Activities of Erythropoietin

Blood, 1991-06, Vol.77 (12), p.2624-2632

1991

Link zum Volltext

Verfügbarkeit prüfen

1 – 19 von 19

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(19)

Sprache

Englisch
(19)
Japanisch
(2)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Results From the First‐in‐Human Study With Ozanimod, a Novel, Selective Sphingosine‐1‐Phosphate Receptor Modulator

Cardiac Safety of Ozanimod, a Novel Sphingosine‐1‐Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study

Rationally Designed High-Affinity 2-Amino-6-halopurine Heat Shock Protein 90 Inhibitors That Exhibit Potent Antitumor Activity

Orally Active Purine-Based Inhibitors of the Heat Shock Protein 90

Antiproliferatiye effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units

Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units

Recombinant human factor IX : Replacement therapy, Prophylaxis, and pharmacokinetics in canine hemophilia B

Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase

Site-directed mutagenesis in human tissue-plasminogen activator. Distinguishing sites in the amino-terminal region required for full fibrinolytic activity and rapid clearance from the circulation

Replacement of finger and growth factor domains of tissue plasminogen activator with plasminogen kringle 1. Biochemical and pharmacological characterization of a novel chimera containing a high affinity fibrin-binding domain linked to a heterologous protein

The disposition of ethiofos (WR-2721) in the isolated perfused rat liver

MRGPRX2 Antagonist EP262 Potently Inhibits Agonist-Induced Mast Cell Degranulation In Vitro and In Vivo

Synthesis and Biological Evaluation of a New Class of Geldanamycin Derivatives as Potent Inhibitors of Hsp90

Sa1222 Results of a Safety and Tolerability Study of Rpc1063, a Novel Orally Administered Sphingosine-1-Phosphate Receptor 1 (S1p1r) Agonist, in Healthy Adult Volunteers

Pharmacokinetics, pharmacodynamics, allometry, and dose selection of rPSGL-Ig for phase I trial

358 A Small Molecule S1P1 Receptor Agonist With Significant Efficacy in Animal Models of Inflammatory Bowel Disease (IBD)

Sa1221 Rpc1063, a Potent, Selective S1P1 Receptor Modulator, Is Active in a Therapeutic IBD Model and Exhibits Favorable PK/PD Properties in Healthy Volunteers

Dimeric ansamycins—A new class of antitumor Hsp90 modulators with prolonged inhibitory activity

The Importance of N- and O-Linked Oligosaccharides for the Biosynthesis and In Vitro and In Vivo Biologic Activities of Erythropoietin

Suchergebnisse filtern